BioSpace News Archive

Business

Retrophin Provides Corporate Update and 2019 Outlook

Top-line readout of pivotal FORT Study in PKAN expected 3Q19

January 8, 2019
·
7 min read
Deals

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets

January 8, 2019
·
15 min read
Biotech Bay

Apollomics, Inc. (previously CBT Pharmaceuticals, Inc.) Raises $100 Million in Series B Financing

Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs

January 8, 2019
·
3 min read
Drug Development

STERNA BIOLOGICALS PREPARES FOR PHASE IIb CLINICAL PROGRAM WITH GATA-3 ANTAGONIST DRUG CANDIDATES SB010 IN ASTHMA AND SB012 IN ULCERATIVE COLITIS

Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US

January 8, 2019
·
5 min read
Business

MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.

January 8, 2019
·
3 min read
Business

MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3

Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types

January 8, 2019
·
3 min read
Business

AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies

Agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology

January 8, 2019
·
4 min read
EVOTEC INVESTS IN FINANCING ROUND OF EXSCIENTIA

$ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC

January 8, 2019
·
5 min read
Drug Development

Novartis Talks Move to Cell and Gene Therapies at JPM

In an interview with CNBC Monday, Novartis Chief Executive Officer Vas Narasimhan noted that the company is looking to become an entity that doesn’t draw its profits from treating disease, but will make money by providing cures.

January 8, 2019
·
3 min read
·
Alex Keown
Business

Seven Former FDA Commissioners Offer Reasons for Agency Independence

In theory, the U.S. Food and Drug Administration (FDA) is tasked with overseeing the safety of food and drugs in the U.S. based on science, not politics. That doesn’t always work.

January 8, 2019
·
3 min read
·
Mark Terry